Expression of Tuberculosis in the Lung

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-09-30

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess lung immune responses in patients with active pulmonary tuberculosis (TB) and in healthy control persons who are exposed to Mycobacterium tuberculosis in households of patients with TB or who are unexposed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis

NCT06580639

Tuberculosis Immunologic Activity Alteration

RECRUITING

Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection

NCT02225158

Latent Tuberculosis Infection

TERMINATED

Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung

NCT05027958

Healthy Latent Tuberculosis Infection (LTBI)

COMPLETED EARLY_PHASE1

Training Protocol on the Natural History of Tuberculosis

NCT01212003

Mycobacterium Infections Tuberculosis, Multidrug-Resistant Latent Tuberculosis +2 more

RECRUITING

Evaluation of Immune Cell Markers in Diagnosis of Tuberculosis

NCT04148053

Tuberculosis Infection

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

M. tuberculosis infects a third of the world's population, and TB is the leading cause of morbidity and mortality due to a single infectious agent. However, only 5% to 10% of M. tuberculosis-infected subjects without an underlying immunodeficiency develop disease during their lifetimes. Therefore protective immunity is induced in the majority of subjects. Understanding correlates of protection against M. tuberculosis in humans is needed to better direct efforts in the development of antituberculosis vaccines.

DESIGN NARRATIVE:

Patients are treated according to good clinical practice; however, no study medications are given as part of the research study. This study involves a one-time bronchoalveolar lavage and venipuncture to obtain immune cells for laboratory studies of immune responses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bronchoalveolar lavages and venipunctures only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TB patients who are 18 to 65 years old
* Clinical and radiographic signs and symptoms consistent with pulmonary TB
* Start date of antituberculous chemotherapy less than 10 days prior to procedures
* Sputum smear positive for acid fast bacilli
* Drug-sensitive, culture-confirmed growth of M. tuberculosis from sputum
* Willing to provide informed consent for participation in bronchoalveolar lavage and venipuncture studies

Exclusion Criteria

* TB patients who have HIV-1 coinfection
* History of any chronic medical condition requiring daily medication (including diabetes mellitus, hypertension, chronic infections, renal or cardiac failure, and peptic ulcer disease)
* History of asthma or upper or lower respiratory tract infection within 2 months of the study
* Hemoglobin level less than 10g/dl

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No